Evercore ISI Sticks to Their Buy Rating for NovoCure (NVCR)

Evercore ISI analyst Vijay Kumar maintained a Buy rating on NovoCure today and set a price target of $25.00. The company’s shares opened today at $14.50.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Kumar is a 3-star analyst with an average return of 1.3% and a 49.45% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Agilent, and Azenta.

In addition to Evercore ISI, NovoCure also received a Buy from H.C. Wainwright’s Emily Bodnar in a report issued on September 30. However, on October 2, TR | OpenAI – 4o reiterated a Hold rating on NovoCure (NASDAQ: NVCR).

NVCR market cap is currently $1.62B and has a P/E ratio of -9.29.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCR in relation to earlier this year. Last month, Ashley Cordova, the CEO of NVCR bought 81,550.00 shares for a total of $996,541.00.